Skip to content

Clinical study on the treatment of ischemic stroke (qi deficiency and blood stasis) in brain capsule.

A randomized, double-blind, double-blind, double-blind, parallel, multi-center clinical trial on the efficacy and biological basis of the treatment of ischemic apoplexy (qi deficiency and blood stasis).

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015189
Enrollment
Unknown
Registered
2018-03-13
Start date
2018-03-15
Completion date
Unknown
Last updated
2018-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke (qi deficiency and blood stasis)

Interventions

Fu Yang also five soup group.:1 drug: capsule emulsifier (op, 4 grains /tid) +2 drug: fuyang also 5 soup granules (op, 1 bag /tid)
Brain capsule group.:Drug 1: brain heart capsule (op, 4 grain /tid) +2: particle emulsifier (op, 1 bag /tid)
Nourishing Yin tong brain granule group.:1 drug: capsule emulsifier (op, 4 grains /tid) +2 drug: nourishing Yin toning granule (op, 1 bag /tid)
placebo group:1 drug: capsule emulsifier (op, 4 pills /tid) +2: granule emulsifier (op, 1 bag /tid)

Sponsors

The First Hospital, Zhejiang University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) conforming to the criteria for diagnosis of ischemic stroke in western medicine; (2) it is in line with the diagnosis of the meridian and qi deficiency blood stasis syndrome in the stroke of traditional Chinese medicine; (3) imaging (CT or MRI) confirmed that the anterior circulation infarction (OCSP clinical classification was complete anterior circulation infarction or partial anterior circulation infarction); (4) course of illness: 1 ~ 4 weeks after onset; (5) using the national institutes of health stroke scale (NIHSS) scoring criteria, 4 points or less than the NIHSS score was less than 20; (6) the history of primary onset or previous cerebral infarction but no disability before this attack (modified Rankin scale score is less than 1); (7) Aged 40 to 80 years old; (8) voluntarily subject to and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) patients with bleeding tendency or bleeding in 3 months, depression after stroke, dementia, cerebral infarction and cerebral hemorrhage after cerebral infarction;Patients with posterior circulation infarction (POCI), transient ischemic attack (TIA), intracranial abnormal vascular network disease, asymptomatic cerebral infarction, large area cerebral infarction vital signs unstable; (2) discontinuation of traditional Chinese medicine for treatment of ischemic stroke for less than 1 week, or after the onset of this disease, thrombolytic therapy was used; (3) merging with other diseases affecting the function of limbs activities, before the treatment with a limp, osteoarthritis, rheumatoid arthritis, gouty arthritis and other physical activities cause dysfunction may affect neural function inspectors; (4) the cerebral embolism caused by cerebral tumor, brain injury, brain host disease, etc., caused by rheumatic heart disease, coronary heart disease and other heart disease combined with atrial fibrillation; (5) before this disease, due to various diseases and weak physical health, it can not independently complete daily activities, etc.; (6) patients with other serious cardiovascular and cerebrovascular diseases, liver, kidney, hematopoietic system, and other patients who have undergone major surgery recently are not suitable for this study. (7) persons with mental illness, severe depression, alcohol dependence or history of drug abuse; (8) within 3 months after the pregnancy, lactation period, or during the period of taking the medicine or taking the medicine; (9) allergic constitution or previous allergy to a variety of drugs, or to the study of the ingredients in the drug; (10) participated in other clinical researchers three months before the trial; (11) the researchers believe that other patients should not be involved in this study.

Design outcomes

Primary

MeasureTime frame
NIHSS;

Secondary

MeasureTime frame
Chinese medicine symptom complex score;mRS;Bathel-Index;

Countries

China

Contacts

Public ContactHou Qun

The First Hospital, Zhejiang University of Traditional Chinese Medicine

houqun168@163.com+86 13588887283

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026